Phase 3 results posted, week of November 9, 2026: 5 industry trials
Industry sponsors posted results for 5 Phase 3 trials on ClinicalTrials.gov so far in the week of November 9 to 15, 2026. Together the trials enrolled 1,272 participants; the largest, Hoffmann-La Roche's SKYSCRAPER-01 trial, enrolled 620.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, November 15, 2026.
The trials
- Hoffmann-La Roche posts results of Phase III tiragolumab trial in NSCLC. Sponsor: Hoffmann-La Roche. Condition: Non-Small Cell Lung Cancer. Interventions: Atezolizumab, Tiragolumab. Phase: Phase 3. Enrollment: 620 (actual). Results first posted November 9, 2026. Record: NCT04294810 (SKYSCRAPER-01).
- Alcon posts results of Phase 3 FID 123320 study. Sponsor: Alcon Research. Conditions: Ocular Redness, Eye Irritation. Intervention: Apraclonidine Hydrochloride Ophthalmic Solution. Phase: Phase 3. Enrollment: 284 (actual). Results first posted November 10, 2026. Record: NCT06538662.
- Alcon posts results of Phase 3 apraclonidine study for ocular redness. Sponsor: Alcon Research. Condition: Ocular Redness. Intervention: Apraclonidine Hydrochloride Ophthalmic Solution. Phase: Phase 3. Enrollment: 159 (actual). Results first posted November 10, 2026. Record: NCT06444529.
- Apellis posts results of Pegcetacoplan long-term safety extension study. Sponsor: Apellis Pharmaceuticals, Inc. Condition: PNH. Intervention: Pegcetacoplan. Phase: Phase 3. Enrollment: 137 (actual). Results first posted November 10, 2026. Record: NCT03531255.
- Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL in China. Sponsor: Genmab. Condition: Diffuse Large B-Cell Lymphoma. Interventions: Epcoritamab, Investigator's Choice Chemotherapy. Phase: Phase 3. Enrollment: 72 (actual). Results first posted November 10, 2026. Record: NCT07226752.
By the numbers
- Trials: 5, from 4 lead sponsors.
- Participants: 1,272 in all across 5 trials; median 159 per trial.
- Largest: Hoffmann-La Roche's SKYSCRAPER-01 trial, 620. Smallest: Genmab's Epcoritamab trial, 72.
- Sponsors with more than one trial: Alcon Research (2).
- Phases as registered: 5 Phase 3.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Registry results are summary data the sponsor posted; the record link opens them in full.